Eli Lilly | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 22.97 B
I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 22.97 B, beating the estimate of USD 20.69 B.
EPS: As of FY2026 Q2, the actual value is USD 7.94, beating the estimate of USD 7.5433.
EBIT: As of FY2026 Q2, the actual value is USD 9.521 B.
The provided reference is a FORM 8-K filing by Eli Lilly and Company, dated August 5, 2026, which indicates that a press release announcing the company’s financial results for the quarter ended June 30, 2026, is attached as Exhibit 99.1. However, the actual financial results, operational metrics, cash flow details, or specific outlook/guidance are not contained within the provided text of this FORM 8-K filing itself. Therefore, no financial or operational metrics can be extracted from the given reference.